FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade

In September 2017, Pfizer filed a lawsuit alleging that J&J was colluding with insurers to ensure the company’s blockbuster autoimmune disease drug, Remicade, was given first preference over its cheaper biosimilar. On Monday, J&J disclosed that the US Federal Trade Commission (FTC) was investigating whether the company had violated antitrust laws, in a regulatory filing.